Literature DB >> 15985570

New and reliable MRI diagnosis for progressive supranuclear palsy.

H Oba1, A Yagishita, H Terada, A J Barkovich, K Kutomi, T Yamauchi, S Furui, T Shimizu, M Uchigata, K Matsumura, M Sonoo, M Sakai, K Takada, A Harasawa, K Takeshita, H Kohtake, H Tanaka, S Suzuki.   

Abstract

OBJECTIVE: To evaluate the area of the midbrain and pons on mid-sagittal MRI in patients with progressive supranuclear palsy (PSP), Parkinson disease (PD), and multiple-system atrophy of the Parkinson type (MSA-P), compare these appearances and values with those of normal control subjects, and establish diagnostic MRI criteria for the diagnosis of PSP.
METHODS: The authors prospectively studied MRI of 21 patients with PSP, 23 patients with PD, 25 patients with MSA-P, and 31 age-matched normal control subjects. The areas of the midbrain tegmentum and the pons were measured on mid-sagittal MRI using the display tools of a workstation. The ratio of the area of the midbrain to the area of the pons was also evaluated in all subjects.
RESULTS: The average midbrain area of the patients with PSP (56.0 mm2) was significantly smaller than that of the patients with PD (103.0 mm2) and MSA-P (97.2 mm2) and that of the age-matched control group (117.7 mm2). The values of the area of the midbrain showed no overlap between patients with PSP and patients with PD or normal control subjects. However, patients with MSA-P showed some overlap of the values of individual areas with values from patients with PSP. The ratio of the area of the midbrain to the area of pons in the patients with PSP (0.124) was significantly smaller than that in those with PD (0.208) and MSA-P (0.266) and in normal control subjects (0.237). Use of the ratio allowed differentiation between the PSP group and the MSA-P group.
CONCLUSION: The area of the midbrain on mid-sagittal MRI can differentiate PSP from PD, MSA-P, and normal aging.

Entities:  

Mesh:

Year:  2005        PMID: 15985570     DOI: 10.1212/01.WNL.0000165960.04422.D0

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  85 in total

Review 1.  Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.

Authors:  Keith A Josephs
Journal:  Mayo Clin Proc       Date:  2017-08       Impact factor: 7.616

2.  Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials.

Authors:  Jennifer L Whitwell; Jia Xu; Jay N Mandrekar; Jeffrey L Gunter; Clifford R Jack; Keith A Josephs
Journal:  Parkinsonism Relat Disord       Date:  2011-11-13       Impact factor: 4.891

Review 3.  MR imaging of midbrain pathologies.

Authors:  E Hattingen; S Blasel; M Nichtweiss; F E Zanella; S Weidauer
Journal:  Clin Neuroradiol       Date:  2010-06-09       Impact factor: 3.649

4.  FAHN/SPG35: a narrow phenotypic spectrum across disease classifications.

Authors:  Tim W Rattay; Tobias Lindig; Jonathan Baets; Katrien Smets; Tine Deconinck; Anne S Söhn; Konstanze Hörtnagel; Kathrin N Eckstein; Sarah Wiethoff; Jennifer Reichbauer; Marion Döbler-Neumann; Ingeborg Krägeloh-Mann; Michaela Auer-Grumbach; Barbara Plecko; Alexander Münchau; Bernd Wilken; Marc Janauschek; Anne-Katrin Giese; Jan L De Bleecker; Els Ortibus; Martine Debyser; Adolfo Lopez de Munain; Aurora Pujol; Maria Teresa Bassi; Maria Grazia D'Angelo; Peter De Jonghe; Stephan Züchner; Peter Bauer; Ludger Schöls; Rebecca Schüle
Journal:  Brain       Date:  2019-06-01       Impact factor: 13.501

5.  Significance of apparent diffusion coefficient measurement for the differential diagnosis of multiple system atrophy, progressive supranuclear palsy, and Parkinson's disease: evaluation by 3.0-T MR imaging.

Authors:  Kazumichi Tsukamoto; Eiji Matsusue; Yoshiko Kanasaki; Suguru Kakite; Shinya Fujii; Toshio Kaminou; Toshihide Ogawa
Journal:  Neuroradiology       Date:  2012-01-25       Impact factor: 2.804

6.  Magnetic resonance imaging in progressive supranuclear palsy.

Authors:  M Stamelou; S Knake; W H Oertel; G U Höglinger
Journal:  J Neurol       Date:  2010-12-22       Impact factor: 4.849

7.  MRI Planimetry and Magnetic Resonance Parkinsonism Index in the Differential Diagnosis of Patients with Parkinsonism.

Authors:  V C Constantinides; G P Paraskevas; G Velonakis; P Toulas; E Stamboulis; E Kapaki
Journal:  AJNR Am J Neuroradiol       Date:  2018-04-05       Impact factor: 3.825

8.  Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.

Authors:  Günter U Höglinger; Jakob Schöpe; Maria Stamelou; Jan Kassubek; Teodoro Del Ser; Adam L Boxer; Stefan Wagenpfeil; Hans-Jürgen Huppertz
Journal:  Mov Disord       Date:  2017-04-24       Impact factor: 10.338

Review 9.  Neurodegenerative dementia and parkinsonism.

Authors:  A Gabelle; F Portet; C Berr; J Touchon
Journal:  J Nutr Health Aging       Date:  2010-01       Impact factor: 4.075

10.  The midbrain to pons ratio: a simple and specific MRI sign of progressive supranuclear palsy.

Authors:  Luke A Massey; Hans R Jäger; Dominic C Paviour; Sean S O'Sullivan; Helen Ling; David R Williams; Constantinos Kallis; Janice Holton; Tamas Revesz; David J Burn; Tarek Yousry; Andrew J Lees; Nick C Fox; Caroline Micallef
Journal:  Neurology       Date:  2013-04-24       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.